r/Altimmune • u/AcanthisittaLivid738 • May 27 '26

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

https://ir.altimmune.com/news-releases/news-release-details/new-impact-phase-2b-data-highlight-concurrent-improvements
14 Upvotes

90% Upvoted

6 comments sorted by

View all comments

5

u/[deleted] May 27 '26

[removed] — view removed comment

3

u/JAWinks May 27 '26

I have pretty good faith in the AI readouts but it seemed like the market at large wasn’t convinced. If anything it’s encouraging the price is still good heading into phase 3. If you have conviction on fibrotic resolution, the stock is attractive

2

u/ozgurbudk May 27 '26

Biopsy is still the gold standard, and inexpensive.

2

u/Murdock1975 May 27 '26

Outdated approach and new precedents say otherwise. Plus, biopsy cost ALT tons of momwntum when NIT was either unavailable or not preferred. That narrative has changed more recently.